Pharmx Technologies Ltd – Fund Manager Investment Commentary & Insights

In February 2026, Naos Asset Management commented that Pharmx Technologies Ltd (ASX:PHX) is a mission-critical pharmaceutical ordering gateway that has launched a new marketplace and a Stockview product to improve order flow and monetisation potential. Across fund manager commentary, the consensus view is that PHX’s entrenched incumbency—used by ~99% of Australian pharmacies and having routed >$20 billion in orders historically—combined with structural tailwinds (digitisation, expanding pharmacy scope of practice and demographic-driven wellness spending) creates a credible opportunity to transition to a higher-margin marketplace and data-led revenue layers, but execution and funding are key risks: managers note the core business currently generates >$2m EBITDA on ~$8m revenue with ~ $4m cash, director alignment (including a 10% holding by Dennis Bastas) and supplier relationships as strengths, while highlighting challenges in re-pricing long-standing flat-fee arrangements, the need to secure diverse supplier participation and transaction volumes, and the importance of early adoption metrics for the marketplace and Stockview (1HFY26 results and uptake are immediate catalysts); strategic considerations for investors are to monitor adoption rates, monetisation mix (flat fee plus usage fees), operational readiness to scale the platform and data services, competitive responses, and whether cash resources and execution timelines are sufficient to convert incumbency into sustainably higher margins given an enterprise valuation of ~$40 million.